Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BioRg3 Innovations
Montreal, Quebec, Canadabiorg3.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BioRg3 Innovations is a Canadian biotechnology company focused on developing therapeutic solutions for rare neuromuscular disorders, particularly Duchenne Muscular Dystrophy (DMD). The company leverages the anti-inflammatory and anti-fibrotic properties of Ginsenoside Rg3, a bioactive compound derived from Panax ginseng, to address muscle degeneration. Their lead program aims to provide a safer and more effective alternative or adjunct to current corticosteroid treatments by inhibiting the NF-kappaB pathway. BioRg3's research is supported by collaborations with academic institutions and Canadian research consortia to advance their candidates toward clinical validation.
- Therapeutic areas
- Rare Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
CQDM
Beyond the preview
Go deeper on BioRg3 Innovations.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioRg3 Innovations.